Zahava Berkowitz1, Sun Hee Rim, Lucy A Peipins. 1. Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Coordinating Center for Health Promotion, Centers for Disease Control and Prevention, 4770 Buford Highway NE, Atlanta, GA 30341, USA. Zberkowitz@cdc.gov
Abstract
OBJECTIVE: To examine the risk of subsequent primary ovarian cancer among women diagnosed previously with cancer (subsequent cohort) and to compare demographic and tumor characteristics affecting overall survival of these women and women diagnosed with first primary ovarian cancer (index cohort). METHODS: We identified the two cohorts of women using the 1973-2005 Surveillance, Epidemiology and End Results (SEER) result data. We calculated relative risk of subsequent primary ovarian cancer and estimated 5-year risks of dying (hazard-ratios) after diagnosis of the first or subsequent primary ovarian cancer in the two cohorts, respectively using Cox modeling. RESULTS: Women diagnosed with index cancers of the corpus uteri, colon, cervix, and melanoma at age younger than 50 had increased risk of ovarian cancer within 5 years after diagnosis (p<0.05); young breast cancer survivors had continued risk beyond 20 years. In 5-year follow-up survival analysis, the factors associated with a better survival (p<0.05) were similar in both cohorts and included more recent diagnosis; localized or regional disease; age <50 years at diagnosis; and being white versus black. A lower risk of dying from mucinous, endometrioid, or non-epithelial tumors than from serous was seen after 15 months (p<0.01), or after 32 months from diagnosis of the index and subsequent cohorts, respectively. CONCLUSIONS: Age, stage, and histology affect ovarian cancer survival. The increased risk of ovarian cancer over time, especially among breast and colon cancer survivors who are less than 50 years of age, suggests common etiologies and necessitates careful surveillance by health care providers and increased survivors awareness through educational efforts. Published by Elsevier Ltd.
OBJECTIVE: To examine the risk of subsequent primary ovarian cancer among women diagnosed previously with cancer (subsequent cohort) and to compare demographic and tumor characteristics affecting overall survival of these women and women diagnosed with first primary ovarian cancer (index cohort). METHODS: We identified the two cohorts of women using the 1973-2005 Surveillance, Epidemiology and End Results (SEER) result data. We calculated relative risk of subsequent primary ovarian cancer and estimated 5-year risks of dying (hazard-ratios) after diagnosis of the first or subsequent primary ovarian cancer in the two cohorts, respectively using Cox modeling. RESULTS:Women diagnosed with index cancers of the corpus uteri, colon, cervix, and melanoma at age younger than 50 had increased risk of ovarian cancer within 5 years after diagnosis (p<0.05); young breast cancer survivors had continued risk beyond 20 years. In 5-year follow-up survival analysis, the factors associated with a better survival (p<0.05) were similar in both cohorts and included more recent diagnosis; localized or regional disease; age <50 years at diagnosis; and being white versus black. A lower risk of dying from mucinous, endometrioid, or non-epithelial tumors than from serous was seen after 15 months (p<0.01), or after 32 months from diagnosis of the index and subsequent cohorts, respectively. CONCLUSIONS: Age, stage, and histology affect ovarian cancer survival. The increased risk of ovarian cancer over time, especially among breast and colon cancer survivors who are less than 50 years of age, suggests common etiologies and necessitates careful surveillance by health care providers and increased survivors awareness through educational efforts. Published by Elsevier Ltd.
Authors: Sun Hee Rim; K Robin Yabroff; Sabitha Dasari; Xuesong Han; Kristin Litzelman; Donatus U Ekwueme Journal: Prev Med Date: 2019-03-16 Impact factor: 4.018
Authors: Sara J Schonfeld; Amy Berrington de Gonzalez; Kala Visvanathan; Ruth M Pfeiffer; William F Anderson Journal: J Clin Oncol Date: 2013-01-02 Impact factor: 44.544
Authors: Lucia Del Mastro; Hatem A Azim; Matteo Lambertini; Marcello Ceppi; Anne-Sophie Hamy; Olivier Caron; Philip D Poorvu; Estela Carrasco; Albert Grinshpun; Kevin Punie; Christine Rousset-Jablonski; Alberta Ferrari; Shani Paluch-Shimon; Angela Toss; Claire Senechal; Fabio Puglisi; Katarzyna Pogoda; Jose Alejandro Pérez-Fidalgo; Laura De Marchis; Riccardo Ponzone; Luca Livraghi; Maria Del Pilar Estevez-Diz; Cynthia Villarreal-Garza; Maria Vittoria Dieci; Florian Clatot; Francois P Duhoux; Rossella Graffeo; Luis Teixeira; Octavi Córdoba; Amir Sonnenblick; Arlindo R Ferreira; Ann H Partridge; Antonio Di Meglio; Claire Saule; Fedro A Peccatori; Marco Bruzzone; Marie Daphne t'Kint de Roodenbeke; Lieveke Ameye; Judith Balmaña Journal: NPJ Breast Cancer Date: 2021-02-12